The Australian government on Thursday changed its CCP virus immunisation advice to recommend that AstraZeneca only be recommended for people aged 60 and over.
This comes after experts found new evidence to suggest that there is a much higher risk of a rare but serious blood clot condition known as thrombosis and thrombocytopenia syndrome (TTS) in the 50-59 age group.
